Emergex is a biotech company focusing on the development of medicines against viral and bacterial infectious diseases, using purely synthetic non-biological components that prime immune cells to destroy pathogen infected cells.
Emergex istackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-cell immune response.
Emergex was founded in 2016 by Professor Thomas Rademacher and Storme Moore-Thornicroft. The company is headquartered in Abingdon, Oxon, United Kingdom.
Emergex is pioneering the development of synthetic ‘set point’ vaccines which prime the T-cell immune response to address some of the world’s most immediate health threats such as COVID-19, Dengue Fever, Zika, Ebola, pandemic flu and serious intra-cellular bacterial infections.
Emergex combines validated technologies together with the very latest scientific insights to develop its vaccines, including using synthetic peptide codes determined on actual infected cells and using a proprietary gold nanoparticle carrier system for programming.
Emergex has a growing pipeline of vaccine candidates. The most advanced development programme is a vaccine for Dengue Fever, which may also be disease modifying for other Flaviviruses such as the Zika and Yellow Fever viruses.
Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine and a Chikungunya vaccine.
Emergex has partnered with the Institute of Molecular and Cell Biology (IMCB) of Singapore to develop a vaccine for the emerging threat of Hand, Foot and Mouth (HFM) disease and has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral vaccines.
Emergex is backed by Vickers Venture Partners, Innovate UK, Trend Investment Group and others. The company raised $11M in a new round on Nov 18, 2020. This brings Emergex's total funding to $23.3M to date.